Interleukin‐22 in urinary tract disease – new experimental directions

Bibliographic Details
Main Authors: Molly A Ingersoll, Malcolm R Starkey
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Clinical & Translational Immunology
Online Access:https://doi.org/10.1002/cti2.1143
id doaj-8936e5701a0548e7861ce0296ceac7fb
record_format Article
spelling doaj-8936e5701a0548e7861ce0296ceac7fb2020-11-25T03:37:50ZengWileyClinical & Translational Immunology2050-00682020-01-0196n/an/a10.1002/cti2.1143Interleukin‐22 in urinary tract disease – new experimental directionsMolly A Ingersoll0Malcolm R Starkey1Department of Immunology Institut Pasteur Paris FranceDepartment of Immunology and Pathology Central Clinical School Monash University Melbourne VIC Australiahttps://doi.org/10.1002/cti2.1143
collection DOAJ
language English
format Article
sources DOAJ
author Molly A Ingersoll
Malcolm R Starkey
spellingShingle Molly A Ingersoll
Malcolm R Starkey
Interleukin‐22 in urinary tract disease – new experimental directions
Clinical & Translational Immunology
author_facet Molly A Ingersoll
Malcolm R Starkey
author_sort Molly A Ingersoll
title Interleukin‐22 in urinary tract disease – new experimental directions
title_short Interleukin‐22 in urinary tract disease – new experimental directions
title_full Interleukin‐22 in urinary tract disease – new experimental directions
title_fullStr Interleukin‐22 in urinary tract disease – new experimental directions
title_full_unstemmed Interleukin‐22 in urinary tract disease – new experimental directions
title_sort interleukin‐22 in urinary tract disease – new experimental directions
publisher Wiley
series Clinical & Translational Immunology
issn 2050-0068
publishDate 2020-01-01
url https://doi.org/10.1002/cti2.1143
work_keys_str_mv AT mollyaingersoll interleukin22inurinarytractdiseasenewexperimentaldirections
AT malcolmrstarkey interleukin22inurinarytractdiseasenewexperimentaldirections
_version_ 1724543557204705280